ArticleBMC endocrine disorders2026
Endocan level and its association with glycemic and inflammatory indices in diabetic nephropathy.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndocan is a soluble proteoglycan containing dermatan sulfate is primarily produced by activated endothelium cells. Conflicting studies have not revealed an association between endocan and diabetic nephropathy (DN). The study aimed to assess the associations of endocan levels with glycemic and inflammatory indices in patients with type 2 diabetes mellitus (T2DM) and DN.
methodsThis study included 88 participants; of whom 30 had T2DM, and 30 patients had DN compared with 28 apparently healthy controls. Endocan levels were measured using an ELISA kit. Fasting insulin level was measured using a LIAISON chemiluminescent immunoassay. Glycated hemoglobin (HbA1c) was measured via CLOVER A1c Plus, and fasting blood glucose (FBG) was measured using colorimetric/enzymatic methods. Insulin resistance (IR) was determined via the HOMA-IR calculator. The glycemic indices were calculated as follows: glucose /insulin ratio G/I, quantitative insulin sensitivity check index (QUICKI), McAuley index (MACi), and triglyceride glucose (TyG) index. The systemic immune-inflammation index (SII) and neutrophil-lymphocyte ratio (NLR) were calculated after CBC measurements.
resultsEndocan levels in patients with DN were significantly greater (P < 0.05) than those in the control group. The FBG, HbA1c%, insulin, HOMA-IR, and QUICKI indices in the DN patients were significantly greater than those in T2DM patients and controls. The endocan level in DN group showed a negative correlation with TyG index (r = -0.355, P = 0.045) and HbA1c (r = -0.387, P = 0.035).
conclusionsEndocan may play a role in the pathogenesis and development of DN and could be used as an effective therapeutic target.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.